Abnormal cannabidiol - Revision history

Adm1n at 17:18, 23 February 2015

2015-02-23T17:18:30Z

Adm1n at 15:03, 25 January 2015

2015-01-25T15:03:34Z

Adm1n: Created page with "Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces..."

2015-01-25T15:03:17Z

Created page with "Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces..."

New page

Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the [[CB1]] and [[CB2 receptors]], which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative [[cannabinoid receptor]], although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55.[10] Further research suggests there are yet more additional cannabinoid receptors.

← Older revision		Revision as of 17:18, 23 February 2015
Line 1:		Line 1:
	Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the [[CB1]] and [[CB2 receptors]], which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative [[cannabinoid receptor]], although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55.Further research suggests there are yet more additional cannabinoid receptors.		Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the [[CB1]] and [[CB2 receptors]], which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative [[cannabinoid receptor]], although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55.Further research suggests there are yet more additional cannabinoid receptors.
		+
		+	[[File:abnormal cannabidoil - Weed Depot.jpg\|300px\|thumb\|left\|Abnormal Cannabidiol]]

← Older revision		Revision as of 15:03, 25 January 2015
Line 1:		Line 1:
−	Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the [[CB1]] and [[CB2 receptors]], which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative [[cannabinoid receptor]], although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55.~~[10]~~ Further research suggests there are yet more additional cannabinoid receptors.	+	Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the [[CB1]] and [[CB2 receptors]], which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative [[cannabinoid receptor]], although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55.Further research suggests there are yet more additional cannabinoid receptors.